> Hungary's Gedeon Richter signed a deal with U.S.-based KV Pharmaceutical for licensing rights to some of KV's technologies and products. Report
> The Federal Court of Canada rejected Novapharm's bid to market a generic version of Pfizer's erectile dysfunction drug Viagra. Report
> The recall of nasal versions of Matrixx Initiatives' Zicam cold remedies could cost as much as $10 million, the company's top executive said. Report
> The FDA approved Allergan's Ozurdex treatment for the retinal disease macular edema. Report
> Pharma pumped $28.7 billion into New Jersey's sputtering economy last year even as the largest companies steadily slashed jobs, according to a statewide trade group. Report
> Bristol-Myers Squibb and AstraZeneca joined forces with Diabetes UK to launch a national patient survey on the effects of hypoglycaemia. Report
> The Medicines Company said FDA granted pediatric exclusivity for Angiomax, its anticoagulant, staving off generic competition till September 2010. Report
> Abbott Laboratories and Dey asked a Massachusetts federal court to sanction the U.S. Department of Justice for destroying evidence in a multidistrict wholesale drug pricing case. Report
Biotech News
> Massachusetts-based ImmunoGen is offering 5 million shares of its stock at a price of $7.00 per share. The company is hoping to raise a total of $33 million after underwriting discounts, commissions and expenses. Report
> Aastrom's shares are up on the news that the FDA has lifted a clinical hold on the company's Phase II congestive heart failure trial. Report
> Opko Health has decided to move into vaccine development and diagnostics following a crucial clinical trial failure in opthalmology last March. Report
> The FDA has approved Novartis' Ilaris (also known as canakinumab or ACZ885), a treatment for children and adults with cryopyrin-associated periodic syndrome (CAPS). Report
And Finally... Smart idea? Healthy people should be able to take the anti-hyperactivity drug Ritalin to boost brain power, a UK ethicist says. Report